TrialsgrambetaRCTs are beautiful

RALES

1999

Randomized Aldactone Evaluation Study

In 1,663 patients with severe HFrEF on ACEi, spironolactone 25 mg reduced all-cause mortality compared with placebo.

Result

Efficacy: All-cause mortalityRR 0.70 (95% CI 0.60-0.82) · P < 0.001

Below 1 favours spironolactone 25 mg, above 1 favours placebo.

Event rates
Absolute difference
11 points
NNT
10

Absolute difference and NNT are derived from the event rates.

Also reported: (30% RRR). Gynaecomastia 10%.

Original publication
Subtopic
MRA
Design
Double-blind RCT, terminated early
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
Pitt B, et al. N Engl J Med. 1999;341(10):709-717.doi 10.1056/NEJM199909023411001

Discussion & critique

Pre-eplerenone era. Real-world hyperkalaemia rose sharply after publication (Juurlink BMJ 2004), underscoring the gap between trial protocol and practice monitoring.

Discussed in podcasts